Short Report

Prognostic value of DNA ploidy and automated assessment of stroma fraction in prostate cancer

Elin Ersvær¹, Tarjei S. Hveem¹, Ljiljana Vlatkovic¹,², Bjørn Brennhovd³, Andreas Kleppe¹,⁴, Kari A.R. Tobin¹, Manohar Pradhan¹, Karolina Cyll¹, Håkon Wæhre¹, David J. Kerr⁵ and Håvard E. Danielsen¹,⁴,⁵

¹Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway
²Department of Pathology, Oslo University Hospital, Oslo, Norway
³Department of Urology, Oslo University Hospital, Oslo, Norway
⁴Department of Informatics, University of Oslo, Oslo, Norway
⁵Nuffield Division of Clinical and Laboratory Sciences, University of Oxford, Oxford, UK

The combination of DNA ploidy and automatically estimated stroma fraction has been shown to correlate with recurrence and cancer death in colorectal cancer. We aimed to extend this observation and evaluate the prognostic importance of this combined marker in prostate cancer. DNA ploidy status was determined by image cytometry and the stroma fraction was estimated automatically on hematoxylin and eosin stained sections in three tumor samples from each patient to account for tumor heterogeneity. The optimal threshold for low (≤56%) and high (>56%) stroma fraction was identified in a discovery cohort (n=253). The combined marker was validated in an independent patient cohort (n=259) with biochemical recurrence as endpoint. The combined marker predicted biochemical recurrence independently in the validation cohort. Multivariable analysis showed that the highest risk of recurrence was observed for patients with samples that had both non-diploid ploidy status and a high stroma fraction (hazard ratio: 2.51, 95% confidence interval: 1.18–5.34). In conclusion, we suggest the combination of DNA ploidy and automatically estimated stroma fraction as a prognostic marker for the risk stratification of prostate cancer patients. It may also be a potential generic marker as concurrent results have been described in colorectal cancer.

Introduction

Prostate cancer is characterized by histological changes in the architecture of the glands, which is reflected in the Gleason grading system of such tumors. This system is the most widely used and the strongest available marker of prostate cancer prognosis. However, the degree of intra- and inter-observer variance is considerable.¹,² Large-scale genomic instability assessed by DNA ploidy is both a generic hallmark and an important prognostic marker in several cancer types, including prostate cancer.³,⁴ Patients with nondiploid tumors have an increased risk of poor prognosis compared to patients with diploid tumors,⁴ which is likely caused by the evolutionary advantages of genomic instability.

Prostate carcinoma has a complex tumor microenvironment (TME), which is composed of components such as smooth muscle, carcinoma-associated fibroblasts, collagen fibers, blood vessels and inflammatory cells. Several studies have investigated the importance of the TME in prostate cancer initiation and progression, and carcinoma-associated fibroblasts have been shown to promote epithelial to mesenchymal transition of cancer cells, tumor invasion, angiogenesis and metastasis.⁵–⁷ A
The stroma that surrounds tumor cells can have significant effects on tumor growth and behavior. Another hallmark of cancer is aneuploidy caused by genomic instability, which offers an important prognostic marker in several cancer types. In this study, the authors found that combining these two markers—stromal fraction and DNA ploidy—provided a significant predictor of biochemical recurrence in prostate cancer. The low cost, high throughput, and accuracy of digital analysis using this combined method thus promise to provide improved prognostic biomarkers in prostate cancer.

Materials and Methods

Patients

Independent discovery and validation cohorts were included in our study, which consisted of men with prostate cancer who underwent radical prostatectomy at the Norwegian Radium Hospital, Oslo; a tertiary comprehensive cancer center in Norway. The basis of prostatectomy was preoperative absence of known metastasis, age less than 75 years and life expectancy of at least 10 years. The discovery cohort is described in Supporting Information.

The validation cohort consisted of 287 men operated between 2001 and 2006. A total of 28 patients were excluded from the analyses due to: missing consent (n = 21), missing or less than six weeks follow-up (n = 4) and no tumor material (n = 3). Three tumor blocks were selected for analyses for each patient. Block one and two represented the worst Gleason score and the largest tumor area. The third block was selected randomly from the remaining tumor blocks with a tumor area >0.5 mm². Two patients received neoadjuvant therapy and 16 patients received adjuvant hormonal or radiotherapy within the six first months after surgery. Therapy started more than 6 months after surgery was considered as secondary treatment. The Gleason score was evaluated as a part of the clinical routine.

Our study adhered to the reporting recommendations for tumor marker prognostic studies (REMARK) reporting criteria and was approved by the Norwegian Regional Committees for Medical Research Ethics South-East region (REK numbers S-07443a and 2013/476). Informed consent was obtained from the patients included in the study. Exceptions were made for diseased patients in agreement with the REK requirements.

Image cytometric analysis

Preparation of nuclear monolayers was performed according to a modified Hedley’s method from 50 μm thick, dissected tumor areas (Supporting Information Fig. S1). The DNA ploidy histograms were classified automatically as diploid, tetraploid or aneuploid. The threshold for tetraploid samples was set to 15% of nuclei in the 4c peak in the histogram. Tetraploid and aneuploid samples were grouped as nondiploid in our study, and a tumor was classified as nondiploid if at least one of the analyzed samples were nondiploid.

Stroma fraction analysis

The measure of stroma fraction (Supporting Information Fig. S2) was performed using hematoxylin and eosin (H&E) stained histological sections scanned at 40x with a NanoZoomer digital slide scanner (Hamamatsu Photonics, Hamamatsu, Japan). The tumor areas on the 3 μm thick H&E sections from the discovery cohort were marked on the glass and scanned, whereas the 5 μm thick H&E sections from the validation cohort were scanned and tumor areas were annotated using a custom software tool. All the tumor areas were marked by a pathologist (M.P.).

The area of stroma and epithelial cells was measured within the annotated tumor area and the stroma fraction was estimated in the discovery cohort by evaluating stroma fraction at any amount at ≥0.4 ng/ml, PSA progression. PSA rise was defined as a single PSA ≥ 0.4 ng/ml, PSA rise and PSA progression. PSA rise was defined as PSA ≥ 0.4 ng/ml followed by a subsequent rise by any amount at any future time point, and the date of event was set to the first
measure of PSA ≥ 0.4 ng/ml. PSA progression was defined as either PSA rise or receipt of secondary therapy or development of distant metastasis, whichever was recorded first. Survival distributions were compared using the Mantel–Cox log-rank test in univariable analysis of categorical variables and the Wald’s chi-squared test in univariable analysis of continuous variables and in multivariable analyses. Patients with missing values for any included variable were excluded from the multivariable analyses. The markers of DNA ploidy and stroma fraction were combined as in Danielsen et al.⁹ to constitute three risk groups: (i) diploid and low stroma, (ii) either nondiploid or high stroma and (iii) nondiploid and high stroma. Pearson’s χ² and Mann–Whitney’s U tests were used to evaluate associations. Two-sided p values <0.05 were considered statistically significant. Statistical analyses were performed using R version 3.1.3 (http://www.r-project.org).

### Data availability

The data that support the findings of our study are available on request from the corresponding author. The data are not publicly available due to ethical restrictions.

---

**Table 1. Patients characteristics in the validation cohort—single PSA ≥ 0.4 ng/ml**

| Characteristic                        | All n (%) | No event n (%) | Event n (%) | p-value¹ |
|---------------------------------------|-----------|----------------|-------------|----------|
| Age, median (IQR)                     | 62 (59–66)| 62 (58–66)     | 63 (60–67) | 0.111    |
| Preoperative PSA (ng/ml), median (IQR)| 8 (6–11)  | 8 (6–10)       | 10 (8–14)  | <0.001   |
| Missing                               | 1 (0)     | 1 (1)          | 0 (0)      |          |
| Gleason score                         |           |                |            | <0.001   |
| ≤6                                    | 78 (30)   | 75 (40)        | 3 (4)      |          |
| 3 + 4                                 | 98 (38)   | 69 (37)        | 29 (41)    |          |
| 4 + 3                                 | 54 (21)   | 37 (20)        | 17 (24)    |          |
| ≥8                                    | 29 (11)   | 8 (4)          | 21 (30)    |          |
| Surgical margins                      |           |                |            | <0.001   |
| Absent                                | 165 (64)  | 137 (72)       | 28 (40)    |          |
| Present                               | 92 (36)   | 51 (27)        | 41 (59)    |          |
| Missing                               | 2 (1)     | 1 (1)          | 1 (1)      |          |
| Extracapsular extension               |           |                |            | <0.001   |
| Absent                                | 166 (64)  | 141 (75)       | 25 (36)    |          |
| Present                               | 89 (35)   | 44 (23)        | 45 (64)    |          |
| Missing                               | 4 (2)     | 4 (2)          | 0 (0)      |          |
| Seminal vesicle infiltration          |           |                |            | <0.001   |
| Absent                                | 228 (88)  | 180 (95)       | 48 (69)    |          |
| Present                               | 30 (12)   | 9 (5)          | 21 (30)    |          |
| Missing                               | 1 (0)     | 0 (0)          | 1 (1)      |          |
| Lymph node involvement                |           |                |            | <0.001   |
| Absent                                | 252 (97)  | 188 (99)       | 64 (91)    |          |
| Present                               | 7 (3)     | 1 (1)          | 6 (9)      |          |
| DNA ploidy                            |           |                |            | 0.014    |
| Diploid                               | 188 (73)  | 145 (77)       | 43 (61)    |          |
| Nondiploid                            | 71 (27)   | 44 (23)        | 27 (39)    |          |
| Stroma fraction                       |           |                |            | 0.013    |
| Low                                   | 198 (76)  | 152 (80)       | 46 (66)    |          |
| High                                  | 61 (24)   | 37 (20)        | 24 (34)    |          |
| Ploidy and stroma combined            |           |                |            | 0.003    |
| Diploid and low stroma                | 148 (57)  | 118 (62)       | 30 (43)    |          |
| Nondiploid or high stroma             | 90 (35)   | 61 (33)        | 29 (41)    |          |
| Nondiploid and high stroma            | 21 (8)    | 10 (5)         | 11 (16)    |          |

Due to rounding the numbers may not sum to 100%.

¹Pearson’s χ² test and Mann–Whitney’s U-test were used to evaluate associations.

Abbreviations: IQR, interquartile range.
**Results**

**Discovery cohort**

The clinicopathological characteristics of the patients included in the discovery cohort ($n = 253$) are summarized in Supporting Information Table S1. The cut-off identified as optimal in the discovery cohort was to categorize stroma fraction ≤56% as “low stroma” and >56% as “high stroma” (Supporting Information Fig. S3). Significant results were seen in the univariable analyses of DNA ploidy (hazard ratio [HR] = 2.33, 95% confidence interval [CI] 1.51–3.60), stroma fraction (HR = 1.90, 95% CI 1.23–2.94) and their combination (HR = 2.44, 95% CI 1.30–4.58 in intermediate risk and HR = 4.03, 95% CI 2.12–7.63 in high risk when compared to low risk, Supporting Information Fig. S4).

**DNA ploidy and stroma fraction**

Of the 777 tumor blocks scheduled for analysis, DNA ploidy and stroma fraction were measured in 775 samples, while two were excluded because they did not contain tumor. Less than 200 tumor cell nuclei were present in two samples rendering DNA ploidy status indeterminate, and valid results for both methods were present in 773 samples. Diploid DNA ploidy were excluded because they did not contain tumor. Less than 200 tumor cell nuclei were present in two samples rendering DNA ploidy status indeterminate, and valid results for both methods were present in 773 samples. Diploid DNA ploidy...
were obtained in univariable (Supporting Information Fig. S5 and Table S3) and multivariable analyses (Supporting Information Table S4) using PSA rise and PSA progression as endpoints.

In patients graded with Gleason score 7 (n = 152), neither DNA ploidy, (HR = 0.96, 95% CI 0.51–1.80), stroma fraction (HR = 1.80, 95% CI 0.97–3.34), their combination (HR = 1.09, 95% CI 0.58–2.05 in intermediate risk and HR = 1.87, 95% CI 0.76–4.60 in high risk), nor Gleason score 3 + 4 versus 4 + 3 (HR = 1.22, 95% CI 0.67–2.22) were significant predictors of BCR in univariable analyses. Significant results were obtained for extracapsular extension, seminal vesicle infiltration, surgical margins and lymph node involvement (Supporting Information Table S5).

Stroma fraction was a significant marker of BCR in univariable analysis when PSA rise and PSA progression was used as endpoints in the subgroup of patients with Gleason score 7, however, DNA ploidy and the combined marker was not significant (Supporting Information Table S5).

**Discussion**

We have for the first time demonstrated independent prognostic value of the combination of DNA ploidy and stroma fraction in prostate cancer. The marker stratified patients into low, intermediate and high-risk groups with 10-year PSA-free survival of 78, 63 and 50%. This novel marker may improve risk stratification of patients treated with radical prostatectomy, by offering an objective and time-efficient measure of two tumor characteristics. The marker may therefore add robustness to the set of established markers without adding additional demands on the pathologists. The importance of this combined marker has previously been described in a study of patients with colorectal cancer, and the significant results in our study suggest that the combined marker has a potential as a generic marker of cancer recurrence.

PSA is a commonly used surrogate marker of clinical recurrence after radical prostatectomy, however, only a subset of the patients that develop BCR will experience disease progression and even fewer will die from the disease. A standard definition of BCR does not exist and to allow for comparison with other studies, we included two commonly used BCR endpoints. A single PSA ≥0.4 ng/ml has been described as a reasonable endpoint that excludes patients with detectable PSA who are unlikely to progress, whereas a PSA ≥0.4 ng/ml followed by subsequent rise has been shown to correlate well with the development of distant metastases. Furthermore, we included PSA progression as an endpoint, where the definition was inspired by the work of Mir et al. who used PSA progression as an endpoint in their evaluation of 14 different BCR definitions. The inclusion of secondary treatments seems reasonable in order to correctly account for actual recurrence in cases where PSA registration was limited. Univariable analyses of the marker that combines DNA ploidy and stroma fraction was significant for all classifications were seen in 655 samples, whereas 119 samples were nondiploid. The median stroma fraction was 45% (IQR 40%–51%); low stroma fraction was seen in 691 samples and high stroma fraction in 88 samples.

Nondiploid tumors were observed in 71 (27%) of 259 patients, whereas 61 (24%) of the patients had a tumor with a high stroma fraction. When the two markers were combined, diploid tumors with low stroma fraction were observed for 148 (57%) of the patients. Tumors with either nondiploid or high stroma fraction were observed for 90 (35%) patients, whereas 21 (8%) patients had nondiploid tumors with high stroma fraction.

**Survival analyses**

DNA ploidy (HR = 1.91, 95% CI 1.18–3.09, Fig. 1a), stroma fraction (HR = 2.02, 95% CI 1.23–3.32, Fig. 1b), and their combination (HR = 1.76, 95% CI 1.05–2.93 in intermediate risk and HR = 3.71, 95% CI 1.85–7.43 in high risk when compared to low risk, Fig. 1c), predicted single PSA in univariable analysis (Supporting Information Table S3). In the multivariable analysis, the combination of DNA ploidy and stroma fraction (HR = 0.97, 95% CI 0.55–1.72 in intermediate risk and HR = 2.51, 95% CI 1.18–5.34 in high risk when compared to low risk), Gleason score, extracapsular extension, seminal vesicle infiltration, surgical margins and preoperative PSA were significant predictors of BCR (Table 2). Similar results
endpoints. Furthermore, multivariable analysis demonstrated that the combined marker was an independent predictor of recurrence when BCR was defined as either single PSA or PSA progression. The discrepancy in results obtained by the use of different BCRs may be explained by the inherent uncertainty of estimates related to the relatively low number of patients.21 Furthermore, as BCR is a surrogate marker of recurrence, longer follow-up or a larger cohort is necessary to decide which definition of BCR is the most accurate predictor of clinical recurrence of disease.

Several studies have investigated the importance of the tissue microenvironment (TME) and carcinoma-associated fibroblasts in prostate cancer initiation and progression.7 Ayala et al.10 reported that tumors with either low (<5%) or high (>50%) stroma fraction, evaluated in tissue microarray punches stained with Masson’s trichrome, behaved aggressively compared to patients with a moderate (6–50%) stroma fraction. The identification of TME in H&E stained tissue sections is more difficult compared to trichrome stained tissue samples. However, TME is recognized by higher cellularity and pale eosin stain, compared to smooth muscles that are eosinophilic.11 The stroma fraction in H&E stained tissue sections has only been reported in three independent studies that included diagnostic biopsies of prostate cancer,11–13 where it was shown that a high stroma fraction predicted recurrence or death of prostate cancer.

We used a software-based method to obtain reproducible measures of the stroma fraction in a tumor area annotated on H&E stained tissue sections of radical prostatectomy specimens, thus avoiding inter- and intra-observer variability. We accounted for intra-tumor heterogeneity by analyzing three separate blocks from each prostate22 and validated the method in an independent cohort. The challenges of an accurate visual assessment of stroma fraction can easily be avoided by the use of the objective measure of stroma fraction obtained by this automatic method. Furthermore, as our method quickly estimates the stroma fraction on scans of routine H&E sections, it is a convenient method that can readily be implemented in the daily clinical practice.

DNA ploidy, a marker of large-scale genomic aberration, is a prognostic marker for many cancers.4 In line with our results, the prognostic importance of DNA ploidy in prostate cancer has earlier been demonstrated in univariable analyses, however, independent prognostic value has not always been seen in multivariable analyses,3,4 which may be explained by the high prognostic power of Gleason grading and other clinicopathological factors.

Gleason grade is one of the best predictors of recurrence in the hands of expert pathologists. However, in a clinical setting, this subjective method depends on the pathologist’s expertise and the important distinction in terms of prognosis between patients with Gleason score 3 + 4 and 4 + 3 can be hampered by the reproducibility of Gleason grading. In agreement with previous reports,10,11 a high stroma fraction predicted a higher risk of recurrence in univariable analyses of patients with Gleason score 7 when PSA rise and PSA progression was used as endpoints, whereas the corresponding result for single PSA was borderline significant (Supporting Information Table S5).

A novel marker composed of DNA ploidy and stroma fraction might supplement the existing risk stratification tools by providing objective and more robust risk assessments for prostate cancer patients treated with radical prostatectomy. The marker combines a measure of large-scale genomic instability with a broad measure of the TME. The threshold of high stroma was determined in a cohort treated with radical prostatectomy with clinical recurrence as endpoint and validated in an independent radical prostatectomy cohort where the combined marker consistently predicted recurrence across different definitions of BCR.

Acknowledgements

The authors would like to thank Marna Lill Kjaereng, Hans Martin Mohn, Rolf Anders Svvertsen and John Maddison for technical support to measure DNA ploidy and stroma fraction. This work was supported by the South-Eastern Norway Regional Health Authority research fund (grant numbers 2012025 to E.E., 2015070 to T.S.H. and 2013133 to K.C.); and by the Research Council of Norway, through its IKTPLUSS Lighthouse program (grant number 259204 to A.K.).

Conflict of interest

Prof. D.J.K. is a Director of Oxford Cancer Biomarkers. The other authors declare no competing interests.

References

1. Singh RV, Agashe SR, Gosavi AV, et al. Interobserver reproducibility of Gleason grading of prostatic adenocarcinoma among general pathologists. Indian J Cancer 2011;48: 488–95.
2. Melia J, Moseley R, Ball RY, et al. A UK-based investigation of inter- and intra-observer reproducibility of Gleason grading of prostatic biopsies. Histopathology 2006;48:644–54.
3. Böcking A, Tih M, Schramm M, et al. DNA-cytometric grading of prostate cancer Systematic review with descriptive data analysis. Pathol Discov 2014;2:1–25.
4. Danielsen HE, Pradhan M, Novelli M. Revisiting tumour aneuploidy—the place of ploidy assessment in the molecular era. Nat Rev Clin Oncol 2016;13:291–304.
5. Tuxhorn JA, Ayala GE, Rowley DR. Reactive stroma in prostate cancer progression. J Urol 2001;166:2472–83.
6. Barron DA, Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer 2012;19: R187–204.
7. Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer 2016;16:582–98.
8. Huijbers A, Tollenaar RA, v Pelt GW, et al. The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol 2013; 24:179–85.
9. Danielsen HE, Hvem T, Domingo E, et al. Prognostic markers for colorectal cancer: estimating ploidy and stroma. Ann Oncol 2018;29: 616–23.
10. Ayala G, Tuxhorn JA, Wheeler TM, et al. Reactive stroma as a predictor of biochemical-free recurrence in prostate cancer. Clin Cancer Res 2003;9: 4792–801.
11. Yanagisawa N, Li R, Rowley D, et al. Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. *Hum Pathol* 2007;38:1611–20.
12. Billis A, Meirelles L, Freitas LL, et al. Adenocarcinoma on needle prostatic biopsies: does reactive stroma predicts biochemical recurrence in patients following radical prostatectomy? *Int Braz J Urol* 2013;39:320–7.
13. Saeter T, Vlatkovic L, Waaler G, et al. The prognostic value of reactive stroma on prostate needle biopsy: a population-based study. *Prostate* 2015;75:662–71.
14. McShane LM, Altman DG, Sauerbrei W, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). *Br J Cancer* 2005;93:887–91.
15. Cyll K, Callaghan P, Kildal W, et al. Preparing for image based DNA ploidy [Online video]. 2015. Available from: https://www.youtube.com/watch?v=_24EkvYAwOc.
16. Punt CJ, Buyse M, Köhne CH, et al. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. *J Natl Cancer Inst* 2007;99:998–1003.
17. Antonarakis ES, Chen Y, Elsamanoudi SI, et al. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. *BJU Int* 2011;108:378–85.
18. Amling CL, Bergstralh EJ, Blute ML, et al. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? *J Urol* 2001;165:1146–51.
19. Stephenson AJ, Kattan MW, Eastham JA, et al. Defining biochemical recurrence of prostate cancer after radical prostatectomy: a proposal for a standardized definition. *J Clin Oncol* 2006;24:3973–8.
20. Mir MC, Li J, Klink JC, et al. Optimal definition of biochemical recurrence after radical prostatectomy depends on pathologic risk factors: identifying candidates for early salvage therapy. *Eur Urol* 2014;66:204–10.
21. Isaksson A, Wallman M, Göransson H, et al. Cross-validation and bootstrapping are unreliable in small sample classification. *Pattern Recogn Lett* 2008;29:1960–5.
22. Cyll K, Ersvær E, Vlatkovic L, et al. Tumour heterogeneity poses a significant challenge to cancer biomarker research. *Br J Cancer* 2017;117:367–75.